Hjem › Sklerodermi › New York
Sklerodermi kliniske forsøg i New York
11 studier for Sklerodermi søger deltagere på steder i New York.
Byer i New York
Officiel studietekst (engelsk)
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Hospital for Special Surgery, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center-New York Presbyterian Hospital, New York
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07497087Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- og 1 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
RekruttererFase 2/3
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935A Study of AZD0120 in Autoimmune Diseases
- Research Site, New York
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
RekruttererFase 1
Alder 12 til 70 · Alle køn · Opdateret 22. maj 2026 · NCT06308978Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 27. mar. 2026 · NCT03844061Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2025 · NCT05892614Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.